ATLANTA (AP) - A federal vaccine advisory panel has voted to recommend a second vaccine against cervical cancer for girls and young women.
The government last week licensed the vaccine, Cervarix from GlaxoSmithKline, for marketing in the United States. Merck & Co. has had the vaccine Gardasil on the market since 2006.
The committee voted Wednesday. It did not state a preference of one vaccine over the other. But officials noted that while both protect against forms of the virus that cause cervical, vaginal and vulvar cancers, the older Merck vaccine also protects against forms that cause genital warts. Both shots are a three-dose series. The Merck series costs about $390 and Glaxo's costs about $385.
The CDC still has to adopt the new recommendation for it to become official.
Web Search powered by YAHOO!
|
LifestylesLifestyles
Panel recommends 2nd cervical cancer vaccine
ATLANTA (AP) - A federal vaccine advisory panel has voted to recommend a second vaccine against cervical cancer for girls and young women.
By:
|
WNCT
Published: October 21, 2009
Published: October 21, 2009
Email
Facebook
Google
Twitter
Favorites
MoreAdvertisement
View More:
Atlanta,
Cervical Cancer,
Genital Warts,
Glaxosmithkline,
Health_Medical_Pharma,
Merck,
Merck & Co.,
United States,
Usd,
Vaginal And Vulvar Cancers
Not what you're looking for? Try our quick search:
Reader Comments
*Facebook Account Required to Comment. If you are not already logged into Facebook, please click the comment button to do so.Deal of the Day
Advertisement
Interactive Radar
Advertisement
Featured Blogger
Reel Reviews
Updated: 02/09/2012
Nine On Your Side's Phillip Sayblack shares his take on the latest movie and dvd releases.
More Posts by Reel Reviews
Hot Topics on WNCT.com
Advertisement
Advertisement